Kymera Therapeutics, Inc. is a clinical-stage biotechnology company pioneering targeted protein degradation (TPD) to develop a new generation of oral small-molecule medicines that eliminate disease-causing proteins previously unreachable with conventional therapies, particularly in immunology and other high-need areas. By harnessing the body’s natural protein recycling system, Kymera aims to transform treatment paradigms and address unmet patient needs with innovative degrader drugs now advancing in clinical development.

 IPO in August 2020 (NASDAQ: KYMR)